United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,185,729.06. This represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Price Performance
NASDAQ:UTHR opened at $544.10 on Thursday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The firm has a market capitalization of $23.10 billion, a P/E ratio of 20.08, a P/E/G ratio of 1.80 and a beta of 0.57. The business has a 50 day simple moving average of $568.19 and a 200 day simple moving average of $520.67.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the firm earned $6.63 EPS. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.
Hedge Funds Weigh In On United Therapeutics
Analyst Ratings Changes
A number of research analysts recently issued reports on UTHR shares. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Cantor Fitzgerald increased their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.
Check Out Our Latest Report on United Therapeutics
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
- Five stocks we like better than United Therapeutics
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
